PTGES3 and neoplasm: When we matched patients by clinicopathologic variables, including Gleason score, PSA, tumor stage and nodal status, we determined that PTGES3 overexpression was associated with significantly worse metastasis-free survival (MFS) in patients who received adjuvant first-line androgen deprivation therapy (ADT) (with leuprolide or an GnRH agonist) after prostatectomy, but not in patients who did not receive adjuvant ADT after prostatectomy (Fig. 6a,b).